The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Weber, Christopher J.; Carrillo, María C.; Jagust, William; Jack Jr, Clifford R.; Shaw, Leslie M.; Trojanowski, John Q.; Saykin, Andrew J.; Beckett, Laurel A.; Sur, Cyrille; Rao, Naren P.; Chrem Méndez, Patricio Alexis; Black, Sandra E.; Li, Kuncheng; Iwatsubo, Takeshi; Chang, Chiung-Chih; Sosa, Ana Luisa; Rowe, Christopher C.; Perrin, Richard J.; Morris, John C.; Healan, Amanda M. B.

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Weber, Christopher J.; Carrillo, María C.; Jagust, William; Jack Jr, Clifford R.; Shaw, Leslie M.; Trojanowski, John Q.; Saykin, Andrew J.; Beckett, Laurel A.; Sur, Cyrille; Rao, Naren P.; Chrem Méndez, Patricio Alexis; Black, Sandra E.; Li, Kuncheng; Iwatsubo, Takeshi; Chang, Chiung-Chih; Sosa, Ana Luisa; Rowe, Christopher C.; Perrin, Richard J.; Morris, John C.; Healan, Amanda M. B.

URI: https://doi.org/10.1002/trc2.12226
https://repositorio.fleni.org.ar/xmlui/handle/123456789/671

Fecha: 2021-12-31

Resumen:

The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

Mostrar el registro completo del ítem